Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines
One measurement of tuberculosis vaccine efficacy in clinical trials is prevention of disease, but different mechanisms can underlie disease prevention. Here, the authors develop a mathematical model that allows to identify mechanisms of action of a vaccine preventing TB disease.
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a7f1b051f94340bf8236bcac2684bf3d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a7f1b051f94340bf8236bcac2684bf3d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a7f1b051f94340bf8236bcac2684bf3d2021-12-02T15:35:27ZBridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines10.1038/s41467-019-13387-92041-1723https://doaj.org/article/a7f1b051f94340bf8236bcac2684bf3d2019-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-13387-9https://doaj.org/toc/2041-1723One measurement of tuberculosis vaccine efficacy in clinical trials is prevention of disease, but different mechanisms can underlie disease prevention. Here, the authors develop a mathematical model that allows to identify mechanisms of action of a vaccine preventing TB disease.Mario TovarSergio ArreguiDessislava MarinovaCarlos MartínJoaquín SanzYamir MorenoNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-10 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Science Q |
| spellingShingle |
Science Q Mario Tovar Sergio Arregui Dessislava Marinova Carlos Martín Joaquín Sanz Yamir Moreno Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| description |
One measurement of tuberculosis vaccine efficacy in clinical trials is prevention of disease, but different mechanisms can underlie disease prevention. Here, the authors develop a mathematical model that allows to identify mechanisms of action of a vaccine preventing TB disease. |
| format |
article |
| author |
Mario Tovar Sergio Arregui Dessislava Marinova Carlos Martín Joaquín Sanz Yamir Moreno |
| author_facet |
Mario Tovar Sergio Arregui Dessislava Marinova Carlos Martín Joaquín Sanz Yamir Moreno |
| author_sort |
Mario Tovar |
| title |
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| title_short |
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| title_full |
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| title_fullStr |
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| title_full_unstemmed |
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| title_sort |
bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines |
| publisher |
Nature Portfolio |
| publishDate |
2019 |
| url |
https://doaj.org/article/a7f1b051f94340bf8236bcac2684bf3d |
| work_keys_str_mv |
AT mariotovar bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines AT sergioarregui bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines AT dessislavamarinova bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines AT carlosmartin bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines AT joaquinsanz bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines AT yamirmoreno bridgingthegapbetweenefficacytrialsandmodelbasedimpactevaluationfornewtuberculosisvaccines |
| _version_ |
1718386553293635584 |